Clinical Trial Update: MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating MFOLFIRINOX plus stereotactic radiotherapy (SBRT) in high-risk and locally advanced pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• mFOLFIRINOX
• stereotactic radiotherapy (SBRT)

Snippet

Sponsor: Australasian Gastro-Intestinal Trials Group | Conditions: Pancreatic Cancer | Phase 2 | Status: UNKNOWN